The Mycetoma Knowledge Gap: Identification of Research Priorities by Sande, W.W.J. (Wendy) van de et al.
Review
The Mycetoma Knowledge Gap: Identification of
Research Priorities
Wendy W. J. van de Sande1*, El Sheikh Maghoub2, Ahmed H. Fahal2, Michael Goodfellow3,
Oliverio Welsh4, Ed Zijlstra5
1 ErasmusMC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands, 2Mycetoma Research Centre, University of Khartoum,
Khartoum, Sudan, 3 School of Biology, University of Newcastle, Newcastle upon Tyne, United Kingdom, 4Dr. Jose E. Gonzalez University Hospital, Universidad Auto´noma
de Nuevo Leo´n, Department of Dermatology, Ave Madero y Ave Gonzalitos, Colonia Mitras Centro, Monterrey, Nuevo Leon, Mexico, 5 Rotterdam Centre for Tropical
Medicine, Rotterdam, The Netherlands
Introduction
Currently there are 17 infections listed by the World Health
Organization as neglected tropical diseases and three others are
cited as neglected conditions [1]. Until July 2013, mycetoma was
absent from the WHO list, even though its estimated prevalence of
two per 100,000 inhabitants was comparable to that of other
recognized neglected diseases, such as Buruli ulcer and Human
African trypanosomiasis [2,3].
Mycetoma is an implantation mycosis [4], characterized by large
tumor-like swellings and located mainly in the extremities. It can be
caused by taxonomically diverse microorganisms, both of bacterial
(actinomycetoma) and fungal origin (eumycetoma) [5]. The most
common causative agents include the fungusMadurella mycetomatis and
the actinomycetes Nocardia brasiliensis, Actinomadura madurae, Streptomyces
somaliensis, and Actinomadura pelletieri [3]. The disease is mainly found in
tropical and subtropical regions of the world, and the majority of
patients are reported fromMexico, Senegal, Sudan, and India, but its
true prevalence and incidence are not well defined [3]. Furthermore,
there are no rapid diagnostic tools, while treatment, especially for
eumycetoma, is unsatisfactory, resulting in high morbidity, including
amputation of limbs (submitted; see Acknowledgments).
On February 1, 2013, a landmark meeting was held in Geneva,
Switzerland that was attended by experts on mycetoma from
around the world. Its aim was to review all currently available
information and to identify knowledge gaps and research
priorities. It was concluded that basic epidemiological information
is lacking: it is not known how many people are suffering from
mycetoma or where the disease is most prevalent. Furthermore,
early detection of mycetoma is difficult, while treatment is far from
satisfactory for eumycetoma patients.
In this paper, we consider the knowledge gaps and research
priorities identified at the Geneva meeting.
Epidemiology
The incidence, prevalence, and mapping of mycetoma
Although mycetoma was first introduced to modern science in
1694 by Kaempfer in his dissertation [6], it is still not known how
many people are affected by this disease. In order to get a rough
estimation on the global burden of mycetoma, van de Sande
performed a meta-analysis in which 8,763 cases were reviewed [3].
These cases were from various countries, including India, Mexico,
Niger, and Sudan [7–16]. By dividing the number of reported
cases by the country population in each year, an estimate of the
prevalence per country was calculated. The estimated prevalence
ranged from 3.49 cases per 100,000 inhabitants in Mauritania to
,0.01 cases per 100,000 inhabitants in many other countries [3].
The estimated prevalence for the endemic areas of mycetoma,
Mexico and Sudan, were 0.15 and 1.81 cases per 100,000
inhabitants, respectively. Although this study gave insight into the
prevalence of mycetoma, the estimates do not reflect the
magnitude of the problem. The total number of patients is
probably much higher, since the prevalence was mainly derived
from single-center studies, and large epidemiological studies from
a number of countries in which mycetoma is known to exist, such
as South Africa, are lacking [3,17–19]. Furthermore, at the
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Abstract
Mycetoma is a tropical disease which is caused by a
taxonomically diverse range of actinomycetes (actinomyce-
toma) and fungi (eumycetoma). The disease was only
recently listed by the World Health Organization (WHO) as
a neglected tropical disease (NTD). This recognition is the
direct result of a meeting held in Geneva on February 1,
2013, in which experts on the disease from around the world
met to identify the key research priorities needed to combat
mycetoma. The areas that need to be addressed are
highlighted here. The initial priority is to establish the
incidence and prevalence of the disease in regions where
mycetoma is endemic, prior to determining the primary
reservoirs of the predominant causal agents and their mode
of transmission to susceptible individuals in order to
establish novel interventions that will reduce the impact of
the disease on individuals, families, and communities.
Critically, economical, reliable, and effective methods are
required to achieve early diagnosis of infections and
consequential improved therapeutic outcomes. Molecular
techniques and serological assays were considered the most
promising in the development of novel diagnostic tools to
be used in endemic settings. Improved strategies for treating
eumycetoma and actinomycetoma are also considered.
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Mycetoma Research Centre in Khartoum, more than 6,400
patients have been seen and treated, but this has not been reported
in the literature (Fahal, in preparation). Surveys performed in
mycetoma-endemic villages in Sudan suggest a prevalence ranging
from 0–8.5 per 1,000 inhabitants (Table 1) [20,21].
It can be concluded from the current situation that (inter)na-
tional surveillance programs are needed to get a reliable indication
of the prevalence of mycetoma. In the first instance, this could be
achieved by using a surveillance form similar to the BU02 (http://
www.who.int/buruli/control/ENG_BU_02.pdf), which is used for
Buruli ulcer [3]. The BU02 form is used to establish the prevalence
of Buruli ulcer in different districts in Cameroon and the
Democratic Republic of Congo (DRC). The Akonolinga district
in Cameroon and the Songololo territory in DRC were found to
have a high prevalence [22,23]. Subsequently, Buruli ulcer control
projects launched in these two locations resulted in an increase in
the number of Buruli cases detected [22,23]. As a result, there was
a significant increase in the proportion of early lesions and simple
ulcerative forms and a decrease in the proportion of relapse cases
[23]. These results indicate that defining areas with a high
prevalence and establishing informed local health institutes
reduces the burden of disease. The application of a similar
approach for mycetoma, including the use of standardized forms
and the establishment of national reference centers, can be
expected to generate more reliable data on the incidence and
prevalence of mycetoma. In Sudan, part of the infrastructure and
data needed are already available. A national Mycetoma Research
Centre is situated in the capital, Khartoum. Furthermore, in 1956,
Abbott already demonstrated that in Atbara, Ed Dueim, and Wad
Medani the prevalence among hospital admissions was higher
than in the capital (prevalence 9.2, 9.3, and 11.8 per 1,000 hospital
admissions, respectively, versus 5.1 in Khartoum) [8]. The
distance from these cities to Khartoum ranges from 190 km to
328 km, making the trip to the Mycetoma Research Centre
difficult and expensive. The late presentation to the clinic is
attributed to the nature of mycetoma, which is usually painless and
slowly progressive, and the lack of health education. Furthermore,
since most of the patients are of low socioeconomic status, financial
constraints also play an important role. Therefore, more patients
will be reached when regional health centers with healthcare
personnel trained in the disease are established in highly endemic
regions. The need was partially realized in October 2012 when a
new Mycetoma center was opened in Wad Medani [24]. However,
more satellite centers are needed in a country as large as Sudan.
Better incidence and prevalence data are necessary to determine
appropriate sites for new mycetoma institutes in the Sudan and
other mycetoma regions, including India, Mexico, and Senegal.
The Mode of Transmission
Other information which is lacking is how people become
infected with the causative agents of mycetoma. The primary
reservoir of the causal agents is believed to be soil. Among the
actinomycetes, A. madurae [25], A. pelletieri [25], N. asteroides [25–
27], N. brasiliensis [25,28], S. somalienis [25,26], and among the
fungi, Falciformispora senegalensis (previously known as Lepto-
sphaeria senegalensis) [25], M. mycetomatis [29], Neotestudina rosatii
[25] and Scedosporium boydii [30–32] have been cultured from
soil, though in many cases it is difficult to be certain that strains
have been correctly identified, especially since they tend not to
have been properly preserved. Several recent attempts to
culture the fungus M. mycetomatis from soil have failed, although
DNA of the organism was detected in 17 out of 74 soil samples
and in one out of 22 thorn samples [33]. There is now evidence
based on phylogenetic analyses that M. mycetomatis may be
closely related to dung-inhabiting fungi, suggesting that its
primary reservoir could overlap with the natural niche of these
fungi [34]. Another mycetoma-causative agent, N. asteroides, has
been isolated from cow dung in India [26]. More studies are
needed to establish the environmental niches of the mycetoma
causative agents and their mode of transmission to patients
(Figure 1).
Irrespective of the natural niche of the causative agent, it has to
reach the subcutaneous tissue in order to cause mycetoma.
Historically, this disease has been associated with minor trauma
caused by thorn pricks, stones, or snake and insect bites [35]. Also,
how the grain itself forms has not been studied. Some studies have
focused on the components of the grain but the formation itself is
not understood [36–39]. The detection of remnants of thorns
inside lesions of mycetoma patients has given credence to the
importance of thorns [35], especially since thorns are abundant in
mycetoma-endemic regions. F. senegalensis and Medicopsis romeroi
(previously known as Pyrenochaeta romeroi) have been isolated from
thorns [35]. However, thorn pricks are also common in people
who do not develop mycetoma, a result which suggests that other
factors may be important and/or that the immune system has a
role in the disease process.
The role of the immune system in mycetoma patients has
been studied to some extent [40–43]. It would seem that there
are no obvious defects in the immune system, but some single
nucleotide polymorphisms have been linked with mycetoma
development [41,42]. Furthermore, from animal experiments it
appears that a Th2-response might be necessary to induce
mycetoma [44–46]. Recently it was demonstrated that a co-
infection with schistosomiasis, a strong Th2-inducer, was linked
to mycetoma susceptibility [47]. The role of animals should be
Table 1. Prevalence of mycetoma as reported in Sudanese villages.*
Village Year Population Number of cases Prevalence per 1,000 Reference
Abu Gumri 1960 1,300 8 6.2 [20]
El Andalous 2011 2,835 24 8.5 [21]
Arkawit 1960 56 0 0 [20]
Beriab 1960 1,350 7 5.2 [20]
Denegila 1960 1,025 1 1.0 [20]
Rabua 1960 500 1 2.0 [20]
Seraam 1960 500 0 0 [20]
*Data obtained mainly from [20].
doi:10.1371/journal.pntd.0002667.t001
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investigated in endemic areas where people live in close contact
with animals (cattle, donkeys, dogs, sheep, chicken, etc.) that are
kept in compounds and where the ground is covered with
animal dung. The role of animal reservoirs has been shown to
be important in the development of many other (subcutaneous)
infections, as exemplified by plague [48], schistosomiasis [49],
Lyme disease [50], and leishmaniaisis [51]. For mycetoma,
intermediate hosts have not been detected, though, interestingly,
N. asteroides, N. otidiscaviarum, and S. somaliensis have been isolated
from the gut and casts of four different earthworm species [26].
Identifying the primary reservoir and the route of infection
could help in developing control strategies to prevent transmis-
sion of the causative agent to the subcutaneous tissue (Figure 1).
Examples of such control measurements for other infectious
diseases are numerous, ranging from mass drug administration to
combat schistosomiasis [52] to distributing bed nets for the
control of malaria [53]. The identification of risk factors
associated with the development of mycetoma could provide
clues to the natural route of infection. Epidemiological screening
and culturing of causative agents from habitats in endemic
regions is needed to answer these questions and plan effective
controls. Easy interventions such as the distribution of closed
shoes, removal of cattle and other animals from the compound,
or clearing thorny bushes from the compound’s immediate
surroundings could possibly prevent mycetoma.
Development of Methods for Early Diagnosis
In order to be able to determine the true burden of mycetoma
and to identify the primary reservoir(s) and potential intermediate
host(s) of its causative agents, good, reliable, fast, and cheap
diagnostic tools are needed. At present, it is very difficult to reliably
discriminate between infected and noninfected individuals in the
field (submitted; see Acknowledgments); early cases without lesions
are almost impossible to identify since they don’t show classical
signs of mycetoma and grains are still absent. The available
diagnostic tools include imaging to determine the extent of lesions
along different tissue planes, and cytological, histopathological
examinations and culturing of grains to identify the causative
agent (submitted; see Acknowledgments). Deep surgical biopsy
material is needed for the latter two procedures. Identification of
causal agents to the species level with histology is next to
Figure 1. Possible hypothesis for mycetoma infection route. At the moment, many questions still remain about the various steps in the
development of mycetoma. First, it is not known where the causative agents reside. What is the natural habitat of these agents? Both soil and dung
have been implicated, but other niches could also be involved. Second, how is the causative agent introduced into the subcutaneous tissue? Is it via a
thorn prick as implicated for years, or are vectors, such as insects, involved? When the causative agent is introduced in the subcutaneous tissue, will it
always cause mycetoma, or does the host play a role as well? Do immune status, genetic background, or co-infections play a role in the development
of mycetoma or even the extent of the infection?
doi:10.1371/journal.pntd.0002667.g001
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impossible, while culturing them is difficult and time-consuming,
especially for nonsporulating fungi (submitted; see Acknowledg-
ments). Misidentification of causal agents in the past has caused
poor therapeutic outcomes [54]. More reliable diagnostic tech-
niques depending on DNA analysis have been developed for the
detection of actinobacterial and fungal causal agents, but such
approaches are too expensive for use in endemic areas at the present
time [55,56]. Therefore, one of the first priorities is to develop fast
and reliable diagnostic tools which can be used as point-of-care tests
in regions where mycetoma is endemic. Since it has been
demonstrated that 65% of all mycetoma cases can be attributed
toM. mycetomatis, N. brasiliensis, A. madurae, A. pelletieri, N. asteroides, and
S. somaliensis, the initial focus should be on the identification of these
causative agents. Diagnostic methods which are most applicable are
DNA-based identification tools such as loop-mediated isothermal
amplification (LAMP), and serological assays.
LAMP has been successfully used in Africa and India [57–59] to
diagnose Human African trypanosomiasis (HAT), malaria and
visceral leishmaniasis. Sufficient DNA can be isolated from a dried
blood spot onWhatman filter paper using simple extraction methods
[58–60]. For the detection of Buruli ulcer, swabs or fine needle
aspirates are used [61]. Isolated DNA can be amplified by using a
heating bath and the resulting amplicons are usually visualized by
adding (fluorescent) dyes [57–61]. This technique might be adapted
for mycetoma, and various patient samples, including blood, serum,
or fine needle aspirates, can be tested to determine the specificity and
sensitivity of this assay in mycetoma patients.
Other diagnostic tools applicable in endemic settings are
serological-based procedures, such as latex bead agglutination
assays and dipsticks. By binding either an antigen [62,63] or a
specific antibody [64,65] of the causative agent to a latex bead, a
cheap and fast screening tool for serum can be developed that
minimally requires the use of any equipment. Latex bead assays
have been developed for other tropical infections, including
visceral leismaniasis [62,64] and paracoccidioidomycosis [63]. In
order to develop a specific agglutination assay, a discriminatory
antigen needs to be selected. Whole genomes are available for N.
brasiliensis [48] and S. somaliensis [47], while those of other causal
agents such as M. mycetomatis and S. sudanensis are being generated.
The genomes of these species will be ideal resources to select
specific proteins for rapid serodiagnosis.
Treatment
Accurate diagnosis of the causal agents of mycetoma is a
prerequisite for proper treatment. The current therapy includes
medical treatment or a combination of medical treatment and
surgery. Prevention by vaccination is not presently available.
Mining the genomes of the most common causative agents could
identify potential vaccine candidates. Currently, actinomycetoma
is treated with antibacterials. The most common drug treatment
for uncomplicated cases is trimethoprim-sulfamethoxazole (TMP-
SMX) given for several months until cure is achieved [66,67]. A
study in the 1970s by Mahgoub evaluated several antimicrobial
combinations in 144 patients with actinomycetoma. In this study,
the best clinical outcome was obtained with sulfamethoxazole
plus streptomycin. This resulted in the following clinical
outcomes: 63.2% cured, 21.5% greatly improved, and 11.1%
showing some improvement [68]. In Sudan, the reported cure
rate was 43.3%, excluding patients who did not complete the
treatment [67]. At present, in Mexico, when there is no
therapeutic response or improvement with TMP-SMX, or when
the infection is severe and disseminated, or in a special location
with a risk of spread to underlying vital tissues (head, neck, trunk,
abdomen, or inguinal region), a combination of amikacin
(15 mg/kg/day) for 3 weeks plus trimethoprim-sulfamethoxazole
(8/40 mg/kg/day) for 5 weeks (a cycle of treatment) is given for
up to five cycles. This treatment has achieved a cure rate of
.90% [66].
For eumycetoma, antifungal therapy consists mainly of ketoco-
nazole or itraconazole combined with surgical excision [67].
Unfortunately, this therapy is not quite successful. A recent study
conducted at the Mycetoma Research Centre in Khartoum,
Sudan showed that of the 1,242 eumycetoma patients studied,
only 321 (25.9%) were cured, 35 (2.8%) had amputations, and 671
of the patients (54%) dropped out from the outpatient follow-up
for various reasons. One of these reasons was the dissatisfaction
with the therapy outcome [67]. In addition, in Sudan, most
patients pay for their treatments. With a monthly income of $60,
the costs of a ketoconazole ($30/month) or itraconazole treatment
($330/month) are a severe financial burden on an average
household. Furthermore, it has been known to cause important
side effects, such as hepatic toxicity, gynaecomastia, and skin
discoloration [69,70]. Many patients stop therapy and are lost to
follow-up in outpatient clinics, only to present later with a massive
relapse, often requiring amputation.
For actinomycetoma, 168 out of 302 patients seen in the
Mycetoma Research Centre in Khartoum did not complete their
treatment. For eumycetoma, the corresponding figures were 671
out of 1,241 patients [67]. Therefore, there is an urgent need to
develop better antifungal therapy, better treatment strategies, and
a shorter treatment regime. A first step in improving therapy has
been made by determining the in vitro susceptibilities of the most
common fungal causative agent M. mycetomatis against a large panel
of marketed antifungal agents [71–75]. M. mycetomatis appeared to
be most susceptible to the azole class of antifungal agents. Only
poor inhibitory concentrations were found for other compounds.
There is now a need to link in vitro susceptibility data with clinical
outcome. There is also a need to generate minimal inhibitory
concentration (MIC) breakpoints for in vitro susceptibility linked
to therapeutic susceptibility or resistance.
In order to improve current therapy for M. mycetomatis
infections, the best approaches are to select safer, newer azoles
to which the organism is susceptible or use treatments that
combine traditionally used azoles with (newly) available antifungal
agents with different targets. Antifungal agents that have been used
clinically in the treatment of eumycetoma include ketoconazole
[76], itraconazole [77], posaconazole [78], voriconazole [79–82],
and terbinafin [83]. The association of an azole with terbinafin is
the most logical combination to be explored, as these two drugs
have a different mode of action. Preliminary data on the use of
liposomal amphotericin B are promising in terms of efficacy with
good drug penetration (Fahal, personal communication). But since
this drug is only available intravenously and is highly expensive, its
feasibility in the long term for mycetoma treatment remains
questionable. As 65% of patients have a secondary bacterial
infection [84], the combination of antifungal and antibacterial
treatment should be explored.
In addition to the application of new drug therapies for
mycetoma, there is a need to shorten treatment times. It is currently
difficult to estimate the duration of antibiotic treatment. Based on
clinical and radiological criteria, a cure is defined as complete
disappearance of the mass, healing of sinuses, skin returned to
normal, bone restored to improved radiological appearance,
absence of hyper-reflective echoes and cavities on ultrasound
examination, and the absence of grains in needle aspirates [67]. The
radiological improvement consists of remolding, absorption of the
sclerotic bone, and reappearance of the normal trabecular pattern
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as well as bone density. A simple, reliable biomarker for cure is
urgently needed to assess the response to treatment.
Conclusion
In order to be able to improve the current management of
mycetoma, we have identified knowledge gaps for which research
is urgently needed. These include the estimation of the burden of
mycetoma in order to focus treatment and care on those locations
with the highest prevalence. Furthermore, identification of the
natural habitat of causal agents and establishing how they are
introduced into subcutaneous tissues could lead to novel interven-
tions, which ultimately will reduce its incidence. The development
of methods for early diagnosis and therapeutic monitoring will
result in better therapeutic outcomes. Improvement of therapeutic
strategies in eumycetoma will also reduce the burden of disease.
Now that the key research priorities have been highlighted, it is
time to implement them. The WHO has taken an important first
step by including mycetoma on the list of NTDs. Further
recognition by the international community is needed. Resources
need to be made available to design control efforts and improve
patient management.
Acknowledgments
The following work, cited in the text above, has been submitted for
publication and is currently under review: van de Sande WWJ, Fahal AH,
Goodfellow M, Mahgoub el S, Welsh O, et al. The merits and pitfalls of the
currently used diagnostic tools in mycetoma. PLOS Negl Trop Dis.
References
1. WHO (2013) The 17 neglected tropical diseases. Geneva: World Health
Organization.
2. Merritt RW, Walker ED, Small PL, Wallace JR, Johnson PD, et al. (2010)
Ecology and transmission of Buruli ulcer disease: a systematic review. PLOS
Negl Trop Dis 4: e911.
3. Van de Sande WWJ (2013) Global burden of human mycetoma: a systematic
review and meta-analysis. PLOS Negl Trop Dis 7: e2550.
4. Queiroz-Telles F, Nucci M, Colombo AL, Tobon A, Restrepo A (2011) Mycoses
of implantation in Latin America: an overview of epidemiology, clinical
manifestations, diagnosis and treatment. Med Mycol 49: 225–236.
5. Ahmed AO, van Leeuwen W, Fahal A, van de Sande WWJ, Verbrugh H, et al.
(2004) Mycetoma caused by Madurella mycetomatis: a neglected infectious burden.
Lancet Infect Dis 4: 566–574.
6. Kaempfer E (1694) Disputatio physica medica inauguralis exhibens decadem
observationem exoticarum [phD thesis]. Netherlands: Univeristy of Leiden.
7. Fahal AH, Sabaa AH (2010) Mycetoma in children in Sudan. Trans R Soc Trop
Med Hyg 104: 117–121.
8. Abbott P (1956) Mycetoma in the Sudan. Trans R Soc Trop Med Hyg 50: 11–
24; discussion, 24–30.
9. Lynch JB (1964) Mycetoma in the Sudan. Ann R Coll Surg Engl 35: 319–
340.
10. Develoux M, Audoin J, Treguer J, Vetter JM, Warter A, et al. (1988) Mycetoma
in the Republic of Niger: clinical features and epidemiology. Am J Trop Med
Hyg 38: 386–390.
11. Bakshi R, Mathur DR (2008) Incidence and changing pattern of mycetoma in
western Rajasthan. Indian J Pathol Microbiol 51: 154–155.
12. Maiti PK, Ray A, Bandyopadhyay S (2002) Epidemiological aspects of
mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med
Int Health 7: 788–792.
13. Chakraborti A, Singh K (1998) Mycetoma in Chandigarh and surrounding
areas. Indian J Med Microbiol 16: 64–65.
14. Lopez Martinez R, Mendez Tovar LJ, Lavalle P, Welsh O, Saul A, et al. (1992)
[Epidemiology of mycetoma in Mexico: study of 2105 cases]. Gac Med Mex
128: 477–481.
15. Joshi KR, Sanghvi A, Vyas MC, Sharma JC (1987) Etiology & distribution of
mycetoma in Rajasthan, India. Indian J Med Res 85: 694–698.
16. Buot G, Lavalle P, Mariat F, Suchil P (1987) [Epidemiologic study of mycetomas
in Mexico. Apropos of 502 cases]. Bull Soc Pathol Exot Filiales 80: 329–339.
17. Culligan GA, Grant C, Robbs GM, Crewe-Brown HH (1985) Actinomadura
pelletieri mycetoma from the Transvaal. A case report. S Afr Med J 68: 416–
418.
18. Freed CC, Bissett E, Martin PM, Ajello L (1975) Actinomycotic mycetoma due
to Streptomyces somaliensis: report of a case in South Africa. Sabouraudia 13:
316–322.
19. Vismer HF, Morrison JG (1974) Mycetoma caused by Actinomadura
(Streptomyces) madurae. The first South African case and the results of
chemotherapy. S Afr Med J 48: 433–437.
20. Murray IG (1968) Laboratory aspects of mycetoma. In: Wolstenholme GEW,
editor. Systemic mycosis. London, WI: J. & A. Churchill Ltd. pp. 78–93.
21. The Federal Ministry of Health: The National Mycetoma Control Programme
(2010) Report on the Epidemiological Study onMycetoma at El Andalous Village,
The White Nile State. Available: http://mycetoma.uofk.edu/news%26events/
pdf/AL%20Andalous%20final%20report.pdf. Accessed 19 February 2014.
22. Porten K, Sailor K, Comte E, Njikap A, Sobry A, et al. (2009) Prevalence of
Buruli ulcer in Akonolinga health district, Cameroon: results of a cross sectional
survey. PLOS Negl Trop Dis 3: e466.
23. Phanzu DM, Suykerbuyk P, Imposo DB, Lukanu PN, Minuku JB, et al. (2011)
Effect of a control project on clinical profiles and outcomes in buruli ulcer: a
before/after study in Bas-Congo, Democratic Republic of Congo. PLOS Negl
Trop Dis 5: e1402.
24. BNNICD (2012) Blue Nile Institute for Communicable diseases (BNNICD)
newsletter. Wad Medani: Blue Nile Institute for Communicable Diseases. 3 p.
Top Five Papers
1. Abbott P (1956) Mycetoma in the Sudan. Trans R Soc
Trop Med Hyg 50: 11–24; discussion, 24–30.
2. Ahmed AO, Mukhtar MM, Kools-Sijmons M, Fahal AH, de
Hoog S, et al. (1999) Development of a species-specific
PCR-restriction fragment length polymorphism analysis
procedure for identification of Madurella mycetomatis. J
Clin Microbiol 37: 3175–3178.
3. van de Sande WWJ, Luijendijk A, Ahmed AO, Bakker-
Woudenberg IA, van Belkum A (2005) Testing of the in
vitro susceptibilities of Madurella mycetomatis to six
antifungal agents by using the sensititre system in
comparison with a viability-based 2,3-bis(2-methoxy-4-
nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetra-
zolium hydroxide (XTT) assay and a modified NCCLS
method. Antimicrob Agents Chemother 49: 1364–1368.
4. Welsh O, Vera-Cabrera L, Welsh E, Salinas MC (2012)
Actinomycetoma and advances in its treatment. Clin
Dermatol 30: 372–381.
5. Mahgoub ES, Gumaa SA (1984) Ketoconazole in the
treatment of eumycetoma due to Madurella mycetomii.
Trans R Soc Trop Med Hyg 78: 376–379.
Key Learning Points
N Obtaining better incidence and prevalence data is
necessary to determine appropriate sites for erecting
mycetoma health care facilities.
N Gaining insight into the natural habitat and the mode of
transmission of the mycetoma causative agents will
open the door to preventive measures to reduce the
number of mycetoma cases worldwide.
N Developing new, fast, and cheap diagnostic tools will
enable early case detection, thereby enhancing the
change of a better therapeutic outcome. Furthermore,
these tools might also be able to monitor the
therapeutic outcome.
N Especially for the treatment of eumyceotma, new
therapeutic options are desperately needed.
PLOS Neglected Tropical Diseases | www.plosntds.org 5 March 2014 | Volume 8 | Issue 3 | e2667
25. Segretain G, Mariat F (1968) [Research on the presence of agents of mycetoma
in the soil and thorny plants of Senegal and Mauritania]. Bull Soc Pathol Exot
Filiales 61: 194–202.
26. Parthasarathi K, Ranganathan LS, Anandi V, Zeyer J (2007) Diversity of
microflora in the gut and casts of tropical composting earthworms reared on
different substrates. J Environ Biol 28: 87–97.
27. Orchard VA, Goodfellow M (1980) Numerical classification of some named
strains of Nocardia asteroides and related isolates from soil. J Gen Microbiol 118:
295–312.
28. Gonzalez-Ochoa A, Sandoval MA (1960) [Isolation of Nocardia brasiliensis and
asteroides from soils]. Rev Inst Salubr Enferm Trop 20: 147–151.
29. Thirumalachar MJ, Padhye AA (1968) Isolation of Madurella mycetomi from soil in
India. Hindustan Antibiot Bull 10: 314–318.
30. Sotgiu G, Mazzoni A, Mantovani A, Ajello L, Palmer J (1966) Survey of soils for
human pathogenic fungi from the Emilia-Romagna region of Italy. II. Isolation
of Allescheria boydii, Cryptococcus neoformans and Histoplasma capsulatum.
Am J Epidemiol 83: 329–337.
31. Ajello L (1952) The isolation of Aliescheria boydii shear, an etiologic agent of
mycetomas, from soil. Am J Trop Med Hyg 1: 227–238.
32. Ajello L, Zeidberg LD (1951) Isolation of Histoplasma capsulatum and Allescheria
boydii from soil. Science 113: 662–663.
33. Ahmed A, Adelmann D, Fahal A, Verbrugh H, van Belkum A, et al. (2002)
Environmental occurrence of Madurella mycetomatis, the major agent of human
eumycetoma in Sudan. J Clin Microbiol 40: 1031–1036.
34. de Hoog GS, Abdalla Ahmed S, Najafzadeh MJ, Sutton DA, Saradeghi Keisari
M, et al. (2013) Phylogenetic findings suggest possible new habitat and routes of
infection of human eumycetoma. PLOS Negl Trop Dis 7: e2229.
35. Fahal AH (2006) Mycetoma, Clinicopathological Monograph. Khartoum:
Khartoum University Press.
36. Findlay GH, Vismer HF (1974) Black grain mycetoma. A study of the chemistry,
formation and significance of the tissue grain in Madurella mycetomi infection.
Br J Dermatol 91: 297–303.
37. Findlay GH, Vismer HF (1977) Black grain mycetoma. Atomic absorption and
spark source mass spectrophotometry of the tissue grain in Madurella mycetomi
infection. Br J Dermatol 97: 497–499.
38. Findlay GH, Vismer HF, Kiebenberg NW (1979) Black grain mycetoma: the
ultrastructure of Madurella mycetomi. Mycopathologia 67: 51–54.
39. Ibrahim AI, El Hassan AM, Fahal A, van de Sande WW (2013) A
histopathological exploration of the Madurella mycetomatis grain. PLOS One
8: e57774.
40. Mahgoub ES, Gumaa SA, El Hassan AM (1977) Immunological status of
mycetoma patients. Bull Soc Pathol Exot Filiales 70: 48–54.
41. van de Sande WW, Fahal A, Verbrugh H, van Belkum A (2007) Polymorphisms
in genes involved in innate immunity predispose toward mycetoma susceptibil-
ity. J Immunol 179: 3065–3074.
42. Mhmoud N, Fahal A, Van de Sande WWJ (2013) Polymorphisms of interleukin-
10 and CCL5 genes in mycetoma. Med Mycol 51: 527–533.
43. Mendez-Tovar LJ, Mondragon-Gonzalez R, Vega-Lopez F, Dockrell HM, Hay
R, et al. (2004) Cytokine production and lymphocyte proliferation in patients
with Nocardia brasiliensis actinomycetoma. Mycopathologia 158: 407–414.
44. Cavanagh LL (1974) Attempts to induce mycetoma in monkeys and mice using
Madurella mycetomi. Sabouraudia 12: 258–262.
45. Ahmed AO, van Vianen W, ten Kate MT, van de Sande WW, van Belkum A, et
al. (2003) A murine model of Madurella mycetomatis eumycetoma. FEMS Immunol
Med Microbiol 37: 29–36.
46. Mahgoub ES (1978) Experimental infection of athymic nude New Zealand mice,
nu nu strain with mycetoma agents. Sabouraudia 16: 211–216.
47. van Hellemond JJ, Vonk AG, de Vogel C, Koelewijn R, Vaessen N, et al. (2013)
Association of eumycetoma and schistosomiasis. PLOS Negl Trop Dis 7: e2241.
48. Prentice MB, Rahalison L (2007) Plague. Lancet 369: 1196–1207.
49. Gryseels B, Polman K, Clerinx J, Kestens L (2006) Human schistosomiasis.
Lancet 368: 1106–1118.
50. Radolf JD, Caimano MJ, Stevenson B, Hu LT (2012) Of ticks, mice and men:
understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat Rev
Microbiol 10: 87–99.
51. Kweku MA, Odoom S, Puplampu N, Desewu K, Nuako GK, et al. (2011) An
outbreak of suspected cutaneous leishmaniasis in Ghana: lessons learnt and
preparation for future outbreaks. Glob Health Action 4. doi:10.3402/
gha.v4i0.5527
52. Zhang Y, MacArthur C, Mubila L, Baker S (2010) Control of neglected tropical
diseases needs a long-term commitment. BMC Med 8: 67.
53. Curtis CF, Maxwell CA, Magesa SM, Rwegoshora RT, Wilkes TJ (2006)
Insecticide-treated bed-nets for malaria mosquito control. J Am Mosq Control
Assoc 22: 501–506.
54. Mhmoud NA, Ahmed SA, Fahal AH, de Hoog GS, Gerrits van den Ende AH,
et al. (2012) Pleurostomophora ochracea, a novel agent of human eumycetoma with
yellow grains. J Clin Microbiol 50: 2987–2994.
55. Ahmed AO, Mukhtar MM, Kools-Sijmons M, Fahal AH, de Hoog S, et al.
(1999) Development of a species-specific PCR-restriction fragment length
polymorphism analysis procedure for identification of Madurella mycetomatis.
J Clin Microbiol 37: 3175–3178.
56. Quintana ET, Wierzbicka K, Mackiewicz P, Osman A, Fahal AH, et al. (2008)
Streptomyces sudanensis sp. nov., a new pathogen isolated from patients with
actinomycetoma. Antonie Van Leeuwenhoek 93: 305–313.
57. Namangala B, Hachaambwa L, Kajino K, Mweene AS, Hayashida K, et al.
(2012) The use of Loop-mediated Isothermal Amplification (LAMP) to detect the
re-emerging Human African Trypanosomiasis (HAT) in the Luangwa and
Zambezi valleys. Parasit Vectors 5: 282.
58. Matovu E, Kuepfer I, Boobo A, Kibona S, Burri C (2010) Comparative
detection of trypanosomal DNA by loop-mediated isothermal amplification and
PCR from flinders technology associates cards spotted with patient blood. J Clin
Microbiol 48: 2087–2090.
59. Surabattula R, Vejandla MP, Mallepaddi PC, Faulstich K, Polavarapu R
(2013) Simple, rapid, inexpensive platform for the diagnosis of malaria by
loop mediated isothermal amplification (LAMP). Exp Parasitol 134: 333–
340.
60. Verma S, Avishek K, Sharma V, Negi NS, Ramesh V, et al. (2013) Application
of loop-mediated isothermal amplification assay for the sensitive and rapid
diagnosis of visceral leishmaniasis and post-kala-azar dermal leishmaniasis.
Diagn Microbiol Infect Dis 75: 390–395.
61. Ablordey A, Amissah DA, Aboagye IF, Hatano B, Yamazaki T, et al. (2012)
Detection of Mycobacterium ulcerans by the loop mediated isothermal amplification
method. PLOS Negl Trop Dis 6: e1590.
62. Akhoundi B, Mohebali M, Shojaee S, Jalali M, Kazemi B, et al. (2013) Rapid
detection of human and canine visceral leishmaniasis: assessment of a latex
agglutination test based on the A2 antigen from amastigote forms of Leishmania
infantum. Exp Parasitol 133: 307–313.
63. Silveira-Gomes F, Sarmento DN, Pinto TM, Pimentel RF, Nepomuceno LB,
et al. (2011) Development and evaluation of a latex agglutination test for the
serodiagnosis of paracoccidioidomycosis. Clin Vaccine Immunol 18: 604–
608.
64. Attar ZJ, Chance ML, el-Safi S, Carney J, Azazy A, et al. (2001) Latex
agglutination test for the detection of urinary antigens in visceral leishmaniasis.
Acta Trop 78: 11–16.
65. Darani HY, Ahmadi F, Zabardast N, Yousefi HA, Shirzad H (2010)
Development of a Latex Agglutination Test as a Simple and Rapid Method
for Diagnosis of Trichomonas vaginalis Infection. Avicenna J Med Biotechnol 2:
63–66.
66. Welsh O, Vera-Cabrera L, Welsh E, Salinas MC (2012) Actinomycetoma and
advances in its treatment. Clin Dermatol 30: 372–381.
67. Zein HA, Fahal AH, Mahgoub el S, El Hassan TA, Abdel-Rahman ME (2012)
Predictors of cure, amputation and follow-up dropout among patients with
mycetoma seen at the Mycetoma Research Centre, University of Khartoum,
Sudan. Trans R Soc Trop Med Hyg 106: 639–644.
68. Mahgoub ES (1976) Medical management of mycetoma. Bull World Health
Organ 54: 303–310.
69. Findor JA, Sorda JA, Igartua EB, Avagnina A (1998) Ketoconazole-induced liver
damage. Medicina (B Aires) 58: 277–281.
70. Bernuau J, Durand F, Pessayre D (1997) Ketoconazole-induced hepatotoxicity.
Hepatology 26: 802.
71. van de Sande WWJ, Fahal AH, Bakker-Woudenberg IAJM, van Belkum A
(2010) Madurella mycetomatis is not susceptible to the echinocandin class of
antifungal agents. Antimicrob Agents Chemother 54: 2738–2740.
72. van de Sande WWJ, Luijendijk A, Ahmed AO, Bakker-Woudenberg IA, van
Belkum A (2005) Testing of the in vitro susceptibilities of Madurella mycetomatis to
six antifungal agents by using the sensititre system in comparison with a viability-
based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-
tetrazolium hydroxide (XTT) assay and a modified NCCLS method.
Antimicrob Agents Chemother 49: 1364–1368.
73. Kloezen W, Meis JF, Curfs-Breuker I, Fahal AH, Van de Sande WWJ (2012) In
vitro antifungal activity of isavuconazole to Madurella mycetomatis. Antimicrob
Agents Chemother 56: 6054–6056.
74. van Belkum A, Fahal AH, van de Sande WW (2011) In vitro susceptibility of
Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents
Chemother 55: 1771–1773.
75. Ahmed AO, van de Sande WWJ, van Vianen W, van Belkum A, Fahal AH, et
al. (2004) In vitro susceptibilities of Madurella mycetomatis to itraconazole and
amphotericin B assessed by a modified NCCLS method and a viability-based
2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetra-
zolium hydroxide (XTT) assay. Antimicrob Agents Chemother 48: 2742–2746.
76. Mahgoub ES, Gumaa SA (1984) Ketoconazole in the treatment of eumycetoma
due to Madurella mycetomii. Trans R Soc Trop Med Hyg 78: 376–379.
77. Fahal AH, Rahman IA, El-Hassan AM, Rahman ME, Zijlstra EE (2011) The
safety and efficacy of itraconazole for the treatment of patients with eumycetoma
due to Madurella mycetomatis. Trans R Soc Trop Med Hyg 105: 127–132.
78. Negroni R, Tobon A, Bustamante B, Shikanai-Yasuda MA, Patino H, et al.
(2005) Posaconazole treatment of refractory eumycetoma and chromoblasto-
mycosis. Rev Inst Med Trop Sao Paulo 47: 339–346.
79. Lacroix C, de Kerviler E, Morel P, Derouin F, Feuilhade de Chavin M (2005)
Madurella mycetomatis mycetoma treated successfully with oral voriconazole.
Br J Dermatol 152: 1067–1068.
80. Loulergue P, Hot A, Dannaoui E, Dallot A, Poiree S, et al. (2006) Successful
treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg 75:
1106–1107.
81. Porte L, Khatibi S, Hajj LE, Cassaing S, Berry A, et al. (2006) Scedosporium
apiospermum mycetoma with bone involvement successfully treated with
voriconazole. Trans R Soc Trop Med Hyg 100: 891–894.
PLOS Neglected Tropical Diseases | www.plosntds.org 6 March 2014 | Volume 8 | Issue 3 | e2667
82. Schaenman JM, Digiulio DB, Mirels LF, McClenny NM, Berry GJ, et al. (2005)
Scedosporium apiospermum soft tissue infection successfully treated with voricona-
zole: potential pitfalls in the transition from intravenous to oral therapy. J Clin
Microbiol 43: 973–977.
83. N’Diaye B, Dieng MT, Perez A, Stockmeyer M, Bakshi R (2006) Clinical efficacy
and safety of oral terbinafine in fungal mycetoma. Int J Dermatol 45: 154–157.
84. Ahmed AO, Abugroun ES (1998) Unexpected high prevalence of secondary
bacterial infection in patients with mycetoma. J Clin Microbiol 36: 850–851.
PLOS Neglected Tropical Diseases | www.plosntds.org 7 March 2014 | Volume 8 | Issue 3 | e2667
